Clinical Trial Update: Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) [Phase 2]

View source ↗

Summary

A multicenter single-arm Phase 2 pilot study evaluating the efficacy of nilotinib in chronic myeloid leukemia patients with molecular relapse after stopping Gli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 2 | Status: COMPLETED